Table 5.
Organ dysfunctions in patients with acute respiratory distress syndrome with low or high plasma endocan levels.
| Endocan ≥ 4.96 ng/mL (n = 15) |
Endocan < 4.96 ng/mL (n = 27) |
P value | ||
|---|---|---|---|---|
| Organ dysfunction (duration of hospital stay) |
||||
| Septic shock, n (%) | 9 (60) | 5 (18.5) | 0.015∗ | |
| Renal failure, n (%) | 8 (53) | 5 (18.5) | 0.035∗ | |
| Coagulopathy, n (%) | 5 (33) | 4 (14.8) | 0.242 | |
| Hepatic dysfunction, n (%) | 4 (27) | 8 (30) | 1.0 | |
| Organ dysfunction (Within 7 days) |
||||
| Septic shock, n (%) | 7 (47) | 3 (11) | 0.020∗ | |
| Renal failure, n (%) | 4 (27) | 2 (7.4) | 0.164 | |
| Coagulopathy, n (%) | 5 (33) | 1 (3.7) | 0.016∗ | |
| Hepatic dysfunction, n (%) | 3 (20) | 3 (11) | 0.649 |
The occurrence of organ dysfunctions was compared in patient groups with low (<4.96 ng/mL) and high (≥4.96 ng/mL) plasma levels of endocan during hospital stay or within 7 days. Asterisk indicates statistically significant difference between patient groups with low and high plasma endocan levels (*P≦0.05;).